Page 136 - 《中国药房》2022年12期

HRR 与非同源末端连接的失衡以及复制叉的保护作用 colorectal cancer[J]. Neoplasia，2020，22（9）：365-375.
等 [57－59] 。通过上述联合用药研究结果来看，PARP 抑制 [13] KAPLAN A R，GUEBLE S E，LIU Y F，et al. Cediranib
剂与放疗或其他药物的结合或许可以克服这种局限。 suppresses homology-directed DNA repair through
通过相关的临床试验，比如定期进行液体活检取样等， down-regulation of BRCA1/2 and RAD51[J]. Sci Transl
Med，2019，11（492）：eaav4508.
及时发现耐药机制并优化靶向药物组合依然是十分必
[14] STECKLEIN S R，KUMARASWAMY E，BEHBOD F，et al.
[59]
要的 。相信随着研究的不断深入，会有更多安全且有
BRCA1 and HSP90 cooperate in homologous and non-
效的 PARP 抑制剂联合干预方案得以应用，从而使更多
homologous DNA double-strand-break repair and G2/M
的患者获益。
checkpoint activation[J]. Proc Natl Acad Sci USA，2012，
参考文献 109（34）：13650-13655.
[ 1 ] D’ANDREAA D. Mechanisms of PARP inhibitor sensitivity [15] SCHOPF F H，BIEBL M M，BUCHNER J. The HSP90
and resistance[J]. DNA Repair（Amst），2018，71：172-176. chaperone machinery[J]. Nat Rev Mol Cell Biol，2017，18
[ 2 ] CURTIN N J，SZABO C. Poly（ADP-ribose）polymerase （6）：345-360.
inhibition：past，present and future[J]. Nat Rev Drug Dis- [16] LIN S S，ZHANG L Y，ZHANG X，et al. Synthesis of novel
cov，2020，19（10）：711-736. dual target inhibitors of PARP and HSP90 and their antitu-
[ 3 ] CHEN Y，DU H. The promising PARP inhibitors in ovarian mor activities[J]. Bioorg Med Chem，2020，28（9）：115434.
cancer therapy：from olaparib to others[J]. Biomed [17] GABBASOV R，BENRUBI I D，O’BRIEN S W，et al.
Pharmacother，2018，99：552-560. Targeted blockade of HSP90 impairs DNA-damage re-
[ 4 ] ZHAN L，QIN Q，LU J，et al. Novel poly（ADP-ribose） sponse proteins and increases the sensitivity of ovarian
polymerase inhibitor，AZD2281，enhances radiosensitivity carcinoma cells to PARP inhibition[J]. Cancer Biol Ther，
of both normoxic and hypoxic esophageal squamous can- 2019，20（7）：1035-1045.
cer cells[J]. Dis Esophagus，2016，29（3）：215-223. [18] PENG Y，WANG Y Y，ZHOU C，et al. PI3K/Akt/mTOR
[ 5 ] PARK Y，CHUI M H，SURYO RAHMANTO Y，et al. Loss pathway and its role in cancer therapeutics：are we making
of ARID1A in tumor cells renders selective vulnerability headway? [J]. Front Oncol，2022，12：819128.
to combined ionizing radiation and PARP inhibitor therapy [19] PHILIP C A，LASKOV I，BEAUCHAMP M C，et al. Inhi-
[J]. Clin Cancer Res，2019，25（18）：5584-5594. bition of PI3K-AKT-mTOR pathway sensitizes endometrial
[ 6 ] HASTAK K，BHUTRA S，PARRY R，et al. Poly（ADP- cancer cell lines to PARP inhibitors[J]. BMC Cancer，
ribose）polymerase inhibitor，an effective radiosensitizer 2017，17（1）：638.
in lung and pancreatic cancers[J]. Oncotarget，2017，8（16）： [20] YANG L，YANG G H，DING Y J，et al. Combined treat-
26344-26355. ment with PI3K inhibitor BKM120 and PARP inhibitor
[ 7 ] WANG L，MASON K A，ANG K K，et al. MK-4827，a olaparib is effective in inhibiting the gastric cancer cells
PARP-1 /-2 inhibitor，strongly enhances response of hu- with ARID1A deficiency[J]. Oncol Rep，2018，40（1）：
man lung and breast cancer xenografts to radiation[J]. In- 479-487.
vest New Drugs，2012，30（6）：2113-2120. [21] BIAN X，GAO J，LUO F，et al. PTEN deficiency sensitizes
[ 8 ] CHAN N，KORITZINSKY M，ZHAO H，et al. Chronic endometrioid endometrial cancer to compound PARP-PI3K
hypoxia decreases synthesis of homologous recombina- inhibition but not PARP inhibition as monotherapy[J]. On-
tion proteins to offset chemoresistance and radioresistance cogene，2018，37（3）：341-351.
[J]. Cancer Res，2008，68（2）：605-614. [22] DE P，SUN Y L，CARLSON J H，et al. Doubling down on
[ 9 ] KUMARESWARAN R，LUDKOVSKI O，MENG A，et al. the PI3K-AKT-mTOR pathway enhances the antitumor ef-
Chronic hypoxia compromises repair of DNA double- ficacy of PARP inhibitor in triple negative breast cancer
strand breaks to drive genetic instability[J]. J Cell Sci， model beyond BRCA-ness[J]. Neoplasia，2014，16（1）：
2012，125（Pt 1）：189-199. 43-72.
[10] BRISTOW R G，HILL R P. Hypoxia and metabolism. Hy- [23] ETHIER C，LABELLE Y，POIRIER G G. PARP-1-in-
poxia，DNA repair and genetic instability[J]. Nat Rev Can- duced cell death through inhibition of the MEK/ERK path-
cer，2008，8（3）：180-192. way in MNNG-treated HeLa cells[J]. Apoptosis，2007，12
[11] LIM J J，YANG K，TAYLOR-HARDING B，et al. VEGFR3 （11）：2037-2049.
inhibition chemosensitizes ovarian cancer stemlike cells [24] SUN C Y，FANG Y，YIN J，et al. Rational combination
through down-regulation of BRCA1 and BRCA2[J]. therapy with PARP and MEK inhibitors capitalizes on
Neoplasia，2014，16（4）：343-353.e1-2. therapeutic liabilities in RAS mutant cancers[J]. Sci
[12] ZHONG L H，WANG R，WANG Y X，et al. Dual inhibi- Transl Med，2017，9（392）：eaal5148.
tion of VEGF and PARP suppresses KRAS-mutant [25] YAZINSKI S A，COMAILLS V，BUISSON R，et al. ATR

·1534 · China Pharmacy 2022 Vol. 33 No. 12 中国药房 2022年第33卷第12期